Skip to main content

Table 1 Clinical Characteristics and Static Pulmonary Function Measurements at Baseline and 1-month Post- LUM/IVA Treatment. Values are median (IQR)

From: Short-term effects of Lumacaftor/Ivacaftor (Orkambi™) on exertional symptoms, exercise performance, and ventilatory responses in adults with cystic fibrosis

 

Baseline

Post-Treatment

Male:Female

3:4

 

Age, years

29 (10)

30 (9)

Height, cm

164 (9)

164 (9)

Mass, kg

59.3 (9.5)

60.3 (9.1)

BMI, kg/m2

20.2 (3.1)

20.5 (3.0)*

SGRQ, total score

37.1 (17.8)

26.3 (16.9)

IPAQ-LF, MET-min/week

2910 (1676)

1754 (3322)

Sweat Chloride, mmol/L

103 (25)

90 (18)*

Pulmonary Function

 FEV1, L

1.44 (0.22)

1.45 (0.45)

 FEV1, %pred

46 (18)

49 (19)

 FVC, L

3.17 (0.49)

3.11 (0.57)

 FVC, %pred

73 (21)

69 (28)

 FEV1/FVC, %

49.1 (10.8)

54.3 (10.3)

 TLC, L

6.17 (1.91)

5.93 (2.10)

 TLC, %pred

97 (17)

100 (27)

 DLCO, mL/mmHg/min

17.4 (6.5)

18.9 (6.6)

 DLCO, %pred

78 (22)

90 (18)

  1. Values are median (IQR). Abbreviations: BMI, body mass index; SGRQ, St. George’s Respiratory Questionnaire Score; IPAQ-LF, International Physical Activity Questionnaire – Long Form; FEV1, forced expired volume in 1 s; FVC, forced vital capacity; TLC, total lung capacity; DLCO, diffusing capacity of the lungs for carbon monoxide (data available in 6 participants);*p < 0.05